nach oben

Annals of Surgical Oncology

Erschienen in:

01.06.2007 | Breast Oncology

Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer

verfasst von: Simon R. Davies, MRCS, Gareth Watkins, BSc, Robert E. Mansel, MS, FRCS, Wen G. Jiang, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial.

Methods

In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients’ clinical outcomes.

Results

WISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer–related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups.

Conclusions

WISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role.

Planque N, Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 2003; 3:15–30PubMedCrossRef

Bringstock D. The CCN family: a new stimulus package. J Endocrinol 2003; 178:169–75CrossRef

Perbal B, Brigstock D, Lau L. Report on the second international workshop on the CCN family of genes. Mol Pathol 2003; 56:80–5PubMedCrossRef

Leask A, Abraham DJ. All in the CCN family: essential matricellular signalling modulators emerge from the bunker. J Cell Sci 2006; 119:4803–10PubMedCrossRef

Xie D, Nakachi K, Wang H, Elashoff R, Koeffler P. Elevated levels of connective tissue growth factor, WISP-1 and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001; 61:8917–23PubMed

Pennica D, Swanson T, Welsh J, et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1 transformed cells and aberrantly expressed in human colon tumours. Proc Natl Acad Sci U S A 1998; 95:14717–22PubMedCrossRef

Khor T, Gul Y, Ithnin H, Seow H. A comparative study of the expression of Wnt-1, WISP-1, surviving and cyclin-D1 in colorectal cancer. Int J Colorectal Dis 2006; 21:291–300PubMedCrossRef

Soon L, Yie T, Shvarts Levine A, Su F, Tchou-Wong K. Overexpression of WISP-1 down regulated motility and invasion of lung cancer cells through inhibition of rac activation. J Biol Chem 2003; 278:11465–70PubMedCrossRef

Banerjee S, Sengupta K, Saxena N, Dhar K, Banerjee S. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-α–positive breast tumour calls through multipul modular cross-talks. Mol Cancer Res 2005; 3:151–62PubMedCrossRef

10.

Banerjee S, Saxena N, Sengupta K, Tawfik O, Mayo M, Banerjee S. WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation. Neoplasia 2003; 5:63–73PubMed

11.

Nessling M, Richter K, Schwaenen C, et al. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 2005; 65:439–47PubMed

12.

Chappell S, Walsh T, Walker RA, Shaw J. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. Br J Cancer 1997; 76:1558–61PubMed

13.

Kleer C, Zhang Q, Lan Q, Merajver S. WISP3 (CCN6) is a gercreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia 2004; 6:179–85PubMedCrossRef

14.

Zhang Y, Pan Q, Zhong H, Merajver S, Kleer C. Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells. Breast Cancer Res 2005; 7:1080–9CrossRef

15.

Hanavadi S, Martin T, Mansel R, Jiang W. Interleukin-11 and its receptor expression in human breast cancer. Ann Surg Oncol 2006; 13:802–8PubMedCrossRef

16.

Martin T, Goyal A, Mansel R, Watkins G, Jiang W. The transcription factor for the E-cadherin complex, Twist, Slug and Snail, in human breast cancer. Ann Surg Oncol 2005; 12:1–9CrossRef

17.

Jiang W, Watkins G, Lane J, et al. Prognostic value of Rho family and rho-GDIs in breast cancer. Clin Can Res 2003; 9:6432–40

18.

Nazarenko A, Bhatnagar S, Hohman R. A closed tube format for amplification and detection of DNA based on energy transfer. Nucleic Acids Res 1997; 25:2516–21PubMedCrossRef

19.

Jiang W, Douglas-Jones A, Mansel R. Level of expression of PPAR-gamma and its co-activator (PPAR-GCA) in human breast cancer. Int J Cancer 2003; 106:752–7PubMedCrossRef

20.

Ye L, Martin T, Parr C, Harrison G, Mansel R, Jiang W. Biphasic effects of 17-β-oestradiol on expression of occluding and transendothelial resistance (TER) and paracellular permiabiliy in human vascular endothelial cells. J Cell Physiol 2003; 196:362–9PubMedCrossRef

21.

King J, Ofori-Acquash A, Stevens T, Al-Mehdi A, Fodstad O, Jiang W. Activated leukocyte adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 2004; 6:478–87CrossRef

22.

Parr C, Watkins G, Jiang W. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 2004; 14:779–86PubMed

23.

Jiang W, Grimshaw D, Lane J, et al. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 2001; 7:2555–62. Erratum in: Clin Cancer Res 2002; 8:300PubMed

24.

Davies G, Jiang W, Mason M. Cell-cell adhesion and signalling intermediates in human prostate cancer. J Urol 2000; 163:985–92PubMedCrossRef

25.

Jiang WG, Watkins G, Fodstad O, et al. Differential expression of the CCN family members Cyr61 from CTGF and Nov in human breast cancer. Endocr Relat Cancer 2004; 11:781–91PubMedCrossRef

26.

Martin TA, Watkins G, Lane J, Jiang WG. Assessing mircovessels and angiogenesis in human cancer, using VE-cadherin. Histopathology 2005; 46:422–30PubMedCrossRef

27.

Davies G, Rmaili K, Jiang WG. Tumour endothelial marker-8 (TEM-8) in human breast cancer: the correlation with angiogenesis. Int J Oncol 2006; 29:1311–7PubMed

28.

Davies G, Mason MD, Mansel RE, Jiang WG. Expression of tumour-endothelial markers in human breast cancer. Clin Exp Metastasis 2004; 21:31–7PubMedCrossRef

29.

Jiang W, Watkins G, Fodsrad O, Douglas-Jones A, Mokbel K, Mansel R. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 2004; 11:781–91PubMedCrossRef

30.

Babic A, Kireeva M, Kolesnikova T, Lau L. CYR61, a product of a growth factor–inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998; 2695:6355–60CrossRef

31.

Mason H, Lake A, Wubben J, Nowak R, Castellot J Jr. The growth arrest–specific gene CCN5 is deficient in human leiomyomas and inhibits the proliferation and motility of cultured human uterine smooth muscle cells. Mol Hum Reprod 2004; 10:181–7PubMedCrossRef

32.

Zoubine M, Banerjee S, Saxena N, Campbell D, Banerjee S. WISP-2: a serum-induible gene differentially expressed in human normal breast epithelial cells and in MCF-7 breast tumor cells. Biochem Biophys Res Commun 2001; 282:421–5PubMedCrossRef

33.

Van Golen K, Davies S, Wu Z, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999; 5:2511–9PubMed

34.

Thorstensen L, Diep C, Meling G, et al. WNT1 inducible signaling pathway protein 3, WISP-3, a novel target gene in colorectal carcinomas with microsatellite instability. Gastroenterology 2001; 121:1275–80PubMedCrossRef

Titel: Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer
verfasst von: Simon R. Davies, MRCS
Gareth Watkins, BSc
Robert E. Mansel, MS, FRCS
Wen G. Jiang, MD
Publikationsdatum: 01.06.2007
Verlag: Springer-Verlag
Erschienen in: Annals of Surgical Oncology / Ausgabe 6/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9376-x

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Association of the Presence of Bone Marrow Micrometastases with the Sentinel Lymph Node Status in 410 Early Stage Breast Cancer Patients: Results of the Swiss Multicenter Study

Merkel Cell Carcinoma: Assessing the Effect of Wide Local Excision, Lymph Node Dissection, and Radiotherapy on Recurrence and Survival in Early-Stage Disease—Results From a Review of 82 Consecutive Cases Diagnosed Between 1992 and 2004

Clinical Correlation of Endoscopic Ultrasonography with Pathologic Stage and Outcome in Patients Undergoing Curative Resection for Gastric Cancer

Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

Should Surgical Resection Be Combined with Imatinib Therapy for Locally Advanced or Metastatic Gastrointestinal Stromal Tumors?

Teaching Palliative Care and End-of-Life Issues: A Core Curriculum for Surgical Residents

Update Chirurgie